Capricor Therapeutics Inc (CAPR)

[RLBLB]

Trial will not start until FDA approves the supplement that CAPR submitted requesting an additional 20 patients added to the already 20 that they approved. So we will have 40 patients for this trial, 20 on CAPR-1002 and 20 on a Placebo. This will give CAPR the blind study. Just a few things that I remembered from the CC pot. So we should be getting a PR stating FDA approved additional 20 patients in the next coming weeks.